DK1453505T3 - Anvendelse af pramipexol til behandling af amyotrofisk lateral sklerose - Google Patents

Anvendelse af pramipexol til behandling af amyotrofisk lateral sklerose

Info

Publication number
DK1453505T3
DK1453505T3 DK02795869.3T DK02795869T DK1453505T3 DK 1453505 T3 DK1453505 T3 DK 1453505T3 DK 02795869 T DK02795869 T DK 02795869T DK 1453505 T3 DK1453505 T3 DK 1453505T3
Authority
DK
Denmark
Prior art keywords
pramipexole
treatment
lateral sclerosis
amyotrophic lateral
als
Prior art date
Application number
DK02795869.3T
Other languages
English (en)
Inventor
James P Bennett Jr
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of DK1453505T3 publication Critical patent/DK1453505T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Noodles (AREA)
  • Artificial Filaments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK02795869.3T 2001-12-11 2002-12-02 Anvendelse af pramipexol til behandling af amyotrofisk lateral sklerose DK1453505T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33938301P 2001-12-11 2001-12-11
US34737102P 2002-01-11 2002-01-11
PCT/US2002/039970 WO2003049705A2 (en) 2001-12-11 2002-12-02 Use of pramipexole to treat amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
DK1453505T3 true DK1453505T3 (da) 2010-11-15

Family

ID=26991607

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02795869.3T DK1453505T3 (da) 2001-12-11 2002-12-02 Anvendelse af pramipexol til behandling af amyotrofisk lateral sklerose

Country Status (20)

Country Link
US (4) US7157480B2 (da)
EP (4) EP2305252A1 (da)
JP (2) JP4500543B2 (da)
KR (1) KR20040066890A (da)
CN (1) CN1617720A (da)
AT (1) ATE480235T1 (da)
AU (1) AU2002360600B2 (da)
CA (1) CA2468747C (da)
CY (1) CY1111237T1 (da)
DE (1) DE60237635D1 (da)
DK (1) DK1453505T3 (da)
ES (2) ES2351303T3 (da)
HK (1) HK1150153A1 (da)
HU (1) HUP0500001A3 (da)
IL (1) IL162408A0 (da)
MX (1) MXPA04005572A (da)
PL (1) PL374310A1 (da)
PT (1) PT1453505E (da)
RU (1) RU2004121177A (da)
WO (1) WO2003049705A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305252A1 (en) * 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
EP1940398A1 (de) * 2005-10-18 2008-07-09 Boehringer Ingelheim International GmbH Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls)
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
CA2652251A1 (en) * 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods for using the same
EP2497473A1 (en) * 2006-05-16 2012-09-12 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and pharmaceutical compositions thereof
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
AU2016210640B2 (en) * 2006-12-14 2018-02-22 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
AU2013209376B2 (en) * 2006-12-14 2016-05-05 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
AU2007333050B2 (en) * 2006-12-14 2013-08-29 Knopp Biosciences Llc Compositions and methods of using (R)-pramipexole
CN101677564A (zh) * 2007-03-14 2010-03-24 诺普神经科学股份有限公司 (6r)-4,5,6,7-四氢-n6-丙基-2,6-苯并噻唑-二胺的改良释放制剂及其使用方法
WO2008113056A2 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
GB0811642D0 (en) * 2008-06-25 2008-07-30 Univ Edinburgh Assay
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
CN102802418A (zh) * 2009-06-19 2012-11-28 诺普神经科学股份有限公司 用于治疗肌萎缩性侧索硬化的组合物和方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
CA2921491C (en) 2012-08-23 2022-06-21 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions and devices
US10874669B2 (en) 2012-11-29 2020-12-29 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
CA2885653A1 (en) * 2012-11-29 2014-06-05 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
EP3681474A1 (en) 2017-09-11 2020-07-22 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for nasal administration of drugs to brain and for systemic effect

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560420A (en) 1896-05-19 Steam and oil separator
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) * 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
UA57004C2 (uk) * 1995-10-26 2003-06-16 Санофі - Сінтелябо Лікувальний засіб, що містить 1-(2-нафт-2-ілетил)-4-(3-трифторметилфеніл)-1,2,3,6,-тетрагідропіридин (варіанти), та спосіб лікування бічного аміотрофічного склерозу
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (de) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
CA2384840A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
EP1303502A2 (en) * 2000-07-06 2003-04-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
WO2002028882A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
EP2305252A1 (en) * 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
WO2003077902A1 (en) * 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
PL1610791T3 (pl) * 2003-03-31 2011-07-29 Titan Pharmaceuticals Inc Wszczepialne urządzenie polimerowe do przedłużonego uwalniania agonisty dopaminy
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
MX2007001850A (es) * 2004-08-13 2007-03-28 Boehringer Ingelheim Int Formulacion de pildora de liberacion prolongada que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para fabricarlo y uso del mismo.
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole

Also Published As

Publication number Publication date
DE60237635D1 (de) 2010-10-21
US20110301210A1 (en) 2011-12-08
US20070105918A1 (en) 2007-05-10
EP2305252A1 (en) 2011-04-06
CA2468747C (en) 2011-05-31
IL162408A0 (en) 2005-11-20
EP1453505B1 (en) 2010-09-08
EP1453505A2 (en) 2004-09-08
EP1453505A4 (en) 2007-01-10
CA2468747A1 (en) 2003-06-19
HUP0500001A3 (en) 2005-11-28
PT1453505E (pt) 2010-12-16
ATE480235T1 (de) 2010-09-15
HUP0500001A2 (hu) 2005-04-28
MXPA04005572A (es) 2004-12-06
CN1617720A (zh) 2005-05-18
CY1111237T1 (el) 2015-06-11
KR20040066890A (ko) 2004-07-27
EP2246053B1 (en) 2013-09-18
JP2005516911A (ja) 2005-06-09
RU2004121177A (ru) 2005-03-10
PL374310A1 (en) 2005-10-03
AU2002360600B2 (en) 2007-11-29
US20130172394A1 (en) 2013-07-04
EP2246053A1 (en) 2010-11-03
US7157480B2 (en) 2007-01-02
US20050032856A1 (en) 2005-02-10
JP2010031059A (ja) 2010-02-12
EP2305253A1 (en) 2011-04-06
ES2351303T3 (es) 2011-02-02
HK1150153A1 (en) 2011-11-04
JP4500543B2 (ja) 2010-07-14
AU2002360600A1 (en) 2003-06-23
ES2432527T3 (es) 2013-12-04
WO2003049705A2 (en) 2003-06-19
WO2003049705A3 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
DK1453505T3 (da) Anvendelse af pramipexol til behandling af amyotrofisk lateral sklerose
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
CY1110259T1 (el) Ανοσορυθμιστης
ATE387197T1 (de) Cyanoalkylamino-derivate als protease-hemmer
DE122007000056I1 (de) Beta-amino-tetrahydroimidazo (1,2-A)pyrazine und-tetrahydrotriazolo(4,3-A)pyrazine als dipeptidyl peptidase Inhibitoren zur Behandlung oder preventionvon Diabetes
BRPI0511875A (pt) uso de compostos de peptìdeo para tratamento da esclerose lateral amiotrófica
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
NO20005032D0 (no) Behandling av parasittsykdommer ved inhibering av cysteinproteaser av papainsuperfamilien
ATE353880T1 (de) Neue verwendung von pyrimidin- oder triazin-2- carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2- carbonsäurenitrilderivate
DE60223923D1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
ID23877A (id) Senyawa-senyawa dan metode-metode untuk penghambatan ekspresi vcam-1
MA27548A1 (fr) Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete.
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
MXPA04003796A (es) Tioacetamidas sustituidas.
BR0209149A (pt) Ftalazinonas
DE69805672T2 (de) Verwendung von Rifaximin als Medikament zur Behandlung von durch Cryptosporidiose verursachten Diarrhoeen
ATE489948T1 (de) Behandlung von autoimmunkrankheiten
DE60306934D1 (de) Verwendung von Nitrilenverbindungen als Arztneimittel
MY139368A (en) Novel cyclohexyl sulphones
DE69838686D1 (de) Tripeptidylpeptidaseinhibitoren
WO2002023784A3 (en) Cysteine protease inhibitors